{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:11:01Z","timestamp":1780413061560,"version":"3.54.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012304","name":"Johns Hopkins School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semradonc.2025.08.004","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:28:07Z","timestamp":1757514487000},"page":"608-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics"],"prefix":"10.1016","volume":"35","author":[{"given":"Maria","family":"Farooq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-9041","authenticated-orcid":false,"given":"Michael J.","family":"Pishvaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.semradonc.2025.08.004_bib0001","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.semradonc.2025.08.004_bib0002","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"Ca"},{"issue":"5","key":"10.1016\/j.semradonc.2025.08.004_bib0003","first-page":"318","article-title":"Recent progress in pancreatic cancer","volume":"63","author":"Wolfgang","year":"2013","journal-title":"CA: Cancer J Clin"},{"issue":"11","key":"10.1016\/j.semradonc.2025.08.004_bib0004","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl j med"},{"issue":"19","key":"10.1016\/j.semradonc.2025.08.004_bib0005","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl j med"},{"issue":"18","key":"10.1016\/j.semradonc.2025.08.004_bib0006","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl j med"},{"issue":"7592","key":"10.1016\/j.semradonc.2025.08.004_bib0007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.semradonc.2025.08.004_bib0008","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-15-0426","article-title":"Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial","volume":"21","author":"Chantrill","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.semradonc.2025.08.004_bib0009","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-17-0899","article-title":"Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype","volume":"23","author":"Lowery","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.semradonc.2025.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.semradonc.2025.08.004_bib0011","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.semradonc.2025.08.004_bib0012","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.795735","article-title":"Deconstructing pancreatic cancer using next generation-omic technologies\u2013from discovery to knowledge-guided platforms for better patient management","volume":"9","author":"Schreyer","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"7540","key":"10.1016\/j.semradonc.2025.08.004_bib0014","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semradonc.2025.08.004_bib0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat rev Gastroenterol hepatol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.08.004_bib0016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat rev Gastroenterol hepatol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.08.004_bib0017","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal transduct target ther"},{"issue":"6273","key":"10.1016\/j.semradonc.2025.08.004_bib0018","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semradonc.2025.08.004_bib0019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p. G12C\u2013mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl j med"},{"issue":"25","key":"10.1016\/j.semradonc.2025.08.004_bib0020","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS G12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J clin oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.08.004_bib0021","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl j med"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0087","series-title":"Preliminary Activity and Safety Results of KRAS G12C Inhibitor glecirasib (JAB-21822) in Patients with Pancreatic Cancer and Other Solid Tumors","author":"Li","year":"2024"},{"issue":"8_Supplement","key":"10.1016\/j.semradonc.2025.08.004_bib0022","doi-asserted-by":"crossref","first-page":"CT028","DOI":"10.1158\/1538-7445.AM2023-CT028","article-title":"Abstract CT028: a first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors","volume":"83","author":"Murciano-Goroff","year":"2023","journal-title":"Cancer res"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-23-PR014","article-title":"Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor treatment","volume":"22","author":"J\u00e4nne","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.semradonc.2025.08.004_bib0024","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS\u2013MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer discov"},{"issue":"4","key":"10.1016\/j.semradonc.2025.08.004_bib0025","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2021","journal-title":"J med chem"},{"issue":"10","key":"10.1016\/j.semradonc.2025.08.004_bib0026","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat med"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0027","doi-asserted-by":"crossref","first-page":"S1273","DOI":"10.1016\/j.annonc.2023.10.025","article-title":"LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann Oncol"},{"issue":"7_Supplement","key":"10.1016\/j.semradonc.2025.08.004_bib0028","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/1538-7445.AM2023-526","article-title":"RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D (ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers","volume":"83","author":"Jiang","year":"2023","journal-title":"Cancer res"},{"issue":"1","key":"10.1016\/j.semradonc.2025.08.004_bib0029","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","article-title":"KRAS (G12D) can be targeted by potent inhibitors via formation of salt bridge","volume":"8","author":"Mao","year":"2022","journal-title":"Cell discov"},{"issue":"11","key":"10.1016\/j.semradonc.2025.08.004_bib0030","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer discov"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0031","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.annonc.2023.09.1838","article-title":"652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI (ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)","volume":"34","author":"Arbour","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0032","series-title":"Patients with RAS Mutant Pancreatic Ductal Adenocarcinoma (PDAC)","article-title":"Safety, Efficacy, and on-treatment Circulating Tumor DNA (ctDNA) Changes from a Phase 1 Study of RMC-6236, a RAS (ON) Multi-selective, Tri-complex Inhibitor","author":"Garrido-Laguna","year":"2025"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0033","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2023-178397","article-title":"RAS MULTI (ON) inhibitor RMC-7977 targets oncogenic RAS mutations and overcomes RAS\/MAPK-mediated resistance to FLT3 inhibitors in AML models","volume":"142","author":"Popescu","year":"2023","journal-title":"Blood"},{"issue":"6_Supplement","key":"10.1016\/j.semradonc.2025.08.004_bib0034","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1158\/1538-7445.AM2024-4709","article-title":"The RASMULTI (ON) inhibitor RMC-7977 blocks downstream MAPK and PI3K pathway activation in KRASG12X_mutant cancers","volume":"84","author":"Bapat","year":"2024","journal-title":"Cancer res"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0035","series-title":"Evaluation of a Novel Pan-RAS\/\u03b2-Catenin Inhibitor, ADT-030, for Treatment of Pancreatic Cancer","author":"Piazza","year":"2024"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0036","series-title":"A Potent and Selective Pan-RAS Inhibitor, ADT-1004, Targeting Complex KRAS Mutations for Pancreatic Cancer","author":"Piazza","year":"2024"},{"issue":"11","key":"10.1016\/j.semradonc.2025.08.004_bib0037","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat rev Clin oncol"},{"issue":"16","key":"10.1016\/j.semradonc.2025.08.004_bib0038","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment","volume":"18","author":"Feig","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.semradonc.2025.08.004_bib0039","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-14-1591","article-title":"Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer","volume":"21","author":"Alagesan","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"13_Supplement","key":"10.1016\/j.semradonc.2025.08.004_bib0040","doi-asserted-by":"crossref","first-page":"CT210","DOI":"10.1158\/1538-7445.AM2021-CT210","article-title":"Abstract CT210: trial in process: phase 1 studies of BI 1701963, a SOS1:: KRAS inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan","volume":"81","author":"Hofmann","year":"2021","journal-title":"Cancer res"},{"issue":"2","key":"10.1016\/j.semradonc.2025.08.004_bib0041","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jtho.2019.12.041","article-title":"A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial","volume":"15","author":"Ou","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0042","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/j.annonc.2023.09.1839","article-title":"653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p. G12C mutated solid tumors","volume":"34","author":"Wang","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.08.004_bib0043","first-page":"1","article-title":"Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1\/2 complexes in pancreatic cancer","volume":"1","author":"Brown","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0044","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0959-8049(22)00881-4","article-title":"ASP3082, a first-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models","volume":"174","author":"Nagashima","year":"2022","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.semradonc.2025.08.004_bib0045","doi-asserted-by":"crossref","first-page":"16432","DOI":"10.1021\/acs.jmedchem.2c01300","article-title":"Development of SOS1 inhibitor-based degraders to target KRAS-mutant colorectal cancer","volume":"65","author":"Bian","year":"2022","journal-title":"J med chem"},{"issue":"27","key":"10.1016\/j.semradonc.2025.08.004_bib0046","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"issue":"7659","key":"10.1016\/j.semradonc.2025.08.004_bib0047","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.semradonc.2025.08.004_bib0048","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat med"},{"issue":"7","key":"10.1016\/j.semradonc.2025.08.004_bib0049","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","article-title":"TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1\/2 trial","volume":"122","author":"Palmer","year":"2020","journal-title":"Br j cancer"},{"issue":"23","key":"10.1016\/j.semradonc.2025.08.004_bib0050","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl j med"},{"issue":"3","key":"10.1016\/j.semradonc.2025.08.004_bib0051","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"10.1016\/j.semradonc.2025.08.004_bib0052","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic mutations in patients with pancreatic cancer","volume":"121","author":"Salo-Mullen","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.semradonc.2025.08.004_bib0053","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer discov"},{"issue":"22","key":"10.1016\/j.semradonc.2025.08.004_bib0054","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-11-0761","article-title":"DNA repair: from genome maintenance to biomarker and therapeutic target","volume":"17","author":"Jalal","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00115","article-title":"Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumor program","volume":"3","author":"Pishvaian","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.08.004_bib0056","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/bjc.2017.19","article-title":"Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer","volume":"116","author":"Golan","year":"2017","journal-title":"Br j cancer"},{"issue":"13","key":"10.1016\/j.semradonc.2025.08.004_bib0057","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J clin oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2025.08.004_bib0058","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","article-title":"An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions","volume":"16","author":"Lowery","year":"2011","journal-title":"oncologist"},{"issue":"3","key":"10.1016\/j.semradonc.2025.08.004_bib0059","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J clin oncol"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00316","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.08.004_bib0061","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl j med"},{"issue":"22","key":"10.1016\/j.semradonc.2025.08.004_bib0062","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J clin oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.08.004_bib0063","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2017.40","article-title":"BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer","volume":"116","author":"Pishvaian","year":"2017","journal-title":"Br j cancer"},{"issue":"2","key":"10.1016\/j.semradonc.2025.08.004_bib0064","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer cell"},{"issue":"6349","key":"10.1016\/j.semradonc.2025.08.004_bib0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semradonc.2025.08.004_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J clin oncol"},{"issue":"7963","key":"10.1016\/j.semradonc.2025.08.004_bib0067","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.semradonc.2025.08.004_bib0068","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer immunol res"},{"issue":"6","key":"10.1016\/j.semradonc.2025.08.004_bib0069","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of lnterleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.semradonc.2025.08.004_bib0070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl j med"},{"issue":"2","key":"10.1016\/j.semradonc.2025.08.004_bib0071","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.08.004_bib0072","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat med"},{"issue":"6","key":"10.1016\/j.semradonc.2025.08.004_bib0073","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-14-2779","article-title":"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients","volume":"21","author":"Yaeger","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.semradonc.2025.08.004_bib0074","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion\u2013positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat med"},{"issue":"10","key":"10.1016\/j.semradonc.2025.08.004_bib0075","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0076","series-title":"Tumor Agnostic Efficacy and Safety of erdafitinib (erda) in Patients (pts) with Advanced Solid Tumors with Prespecified FGFR Alterations (FGFRalt): RAGNAR Primary Analysis","author":"Pant","year":"2023"},{"issue":"2","key":"10.1016\/j.semradonc.2025.08.004_bib0077","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1\u20134 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer discov"},{"issue":"6","key":"10.1016\/j.semradonc.2025.08.004_bib0078","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 fusion\u2013Positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl j med"},{"issue":"6278","key":"10.1016\/j.semradonc.2025.08.004_bib0079","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"6278","key":"10.1016\/j.semradonc.2025.08.004_bib0080","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semradonc.2025.08.004_bib0081","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41467-024-55316-5","article-title":"MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial","volume":"16","author":"Gounder","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2025.08.004_bib0082","doi-asserted-by":"crossref","first-page":"v159","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","volume":"30","author":"Siu","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.08.004_bib0083","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.08.004_bib0084","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.semradonc.2025.08.004_bib0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer discov"},{"issue":"9","key":"10.1016\/j.semradonc.2025.08.004_bib0086","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer discov"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:11:16Z","timestamp":1760227876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1053429625000682"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.08.004","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}